Urban Sester

Urban Sester

Auto-generated profile, based on publicly available information

Urban Sester

Westpfalzklinikum Kaiserslautern, Kaiserslautern, Germany

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TSTina Schmidt
Tina Schmidt
VKVerena Klemis
Verena Klemis
DSDavid Schub
David Schub
JMJanine Mihm
Janine Mihm
FHFranziska Hielscher
Franziska Hielscher
MSMartina Sester
Martina Sester
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. In this observational study we show that, in healthy adult individuals (n = 96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T cells, the levels of which which were significantly higher than after homologous vector vaccine boost (n = 55) and higher or comparable in magnitude to homologous mRNA vaccine regimens (n = 62). Moreover, spike-specific CD8 T cell levels after heterologous vaccination were significantly higher than after both homologous regimens. Spike-specific T cells were predominantly polyfunctional with largely overlapping cytokine-producing phenotypes in all three regimens. Recipients of both the homologous vector regimen and the heterologous vector/mRNA combination reported greater reactogenicity following the priming vector vaccination, whereas heterologous boosting was well tolerated and comparable to homologous mRNA boosting. Taken together, heterologous vector/mRNA boosting induces strong humoral and cellular immune responses with acceptable reactogenicity profiles.

1 April 2013 in Immunity
Verified
Journal Article
Closed access
TSThimoteus Speer
Thimoteus Speer
LRLucia Rohrer
Lucia Rohrer
PBPrzemysław Błyszczuk
Przemysław Błyszczuk
RSRukshana Shroff
Rukshana Shroff
KKKira Kuschnerus
Kira Kuschnerus
ULUlf Landmesser
Ulf Landmesser

9 December 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SZStephen Zewinger
Stephen Zewinger
JRJochen Reiser
Jochen Reiser
VJVera Jankowski
Vera Jankowski
DADalia Alansary
Dalia Alansary
EHEunsil Hahm
Eunsil Hahm
TSThimoteus Speer
Thimoteus Speer

10 April 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
DBDragos Bumbacea
Dragos Bumbacea
SASandra M. Arend
Sandra M. Arend
FEFusun Eyuboglu
Fusun Eyuboglu
JFJay A. Fishman
Jay A. Fishman
DELIA GOLETTIDELIA GOLETTI
DELIA GOLETTI
MSMartina Sester
Martina Sester
Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection withMycobacterium tuberculosisfrom progressing to active disease. The best available proxy for diagnosing latent infection withM. tuberculosisis the identification of an adaptive immune response by the tuberculin skin test or an interferon-γ basedex vivoassay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection withM. tuberculosisin the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positiveM. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking.

1 May 2001 in Transplantation
Verified
Journal Article
Closed access
MSMartina Sester
Martina Sester
USUrban Sester
Urban Sester
BGBarbara Gartner
Barbara Gartner
GHGunnar Heine
Gunnar Heine
MGMatthias Girndt
Matthias Girndt
HKHans Kohler
Hans Kohler
Immunosuppressive treatment in transplant patients frequently causes infectious complications with cytomegalovirus (CMV). The extent of CMV replication can be followed by a number of diagnostic methods. There is, however, no simple diagnostic tool to assess the quality of the cellular antiviral immune response of an individual patient. This would be of particular importance for therapy decisions, as patients with detectable virus load do not necessarily develop CMV-related disease. Using a rapid whole blood assay, the frequencies of CMV-reactive CD4 and CD8 T cells were followed after renal transplantation to characterize their relative contribution in the containment of CMV infection. T cells from transplant patients and healthy control persons were stimulated with CMV antigen in vitro. Based on specific cellular activation and induction of intracellular cytokines, the frequency of CMV-reactive CD4 and CD8 T cells was determined using flow cytometry. Viral load was quantified using the “hybrid-capture” assay. The absence of CMV complications in long-term transplant recipients is reflected by stable virus-specific T-cell frequencies, which do not differ from healthy CMV-positive controls. In contrast, during the first months after transplantation, clinical symptoms are preceded by a decrease in CMV-reactive CD4 T-cell frequencies and an increase in CMV load. The individual immune response and CMV replication are critically balanced and can be characterized by assessing both viral load and antiviral T cells. Our experimental design allows the identification of patients with sufficient, insufficient, or absent T-cell activity and can serve as diagnostic tool to facilitate decisions on antiviral therapy.

1 December 1999 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
MGMatthias Girndt
Matthias Girndt
USUrban Sester
Urban Sester
MSMartina Sester
Martina Sester
HKHarald Kaul
Harald Kaul
HKHans Köhler
Hans Köhler
Patients with chronic renal failure are at high-risk for activation in renal failure patients. Obviously, there infectious complications, similar to patients with other are also alterations of antigen-unspecific immune mech- types of acquired immune defects or those on immuno- anisms, e.g. phagocyte function, but these will not be suppressive therapy. Secondary immune failure in discussed here. The original observation of reduced uraemia is multi-faceted and is influenced by uraemic responses to hepatitis B vaccination (1) was comple- intoxication per se, by altered renal metabolism of mented by documentation of hyporesponsiveness to immunologically active proteins and by specific eVects other vaccines such as tetanus or diphtheria. Non of renal replacement therapy. Large interindividual response to vaccination is closely associated with an variability points to the importance of individual fac- impaired proliferation of T-cells in vitro and a reduced tors. A high incidence of infection is found in uraemic production of the autocrine T-cell growth promoting patients and infections remain the second most fre- cytokine interleukin-(IL-)2 (2,3). Activation of helper quent cause of death. T-cells is needed for both cellular and antibody One specific problem is hepatitis B. Vaccination responses to T-cell-dependent antigens such as those against hepatitis B is routinely performed in dialysis tested in the vaccination trials. Only a few antigens patients. Although eVective in only 60-70% of patients, lead to T-cell independent production of antibodies it helped to eliminate the threat of hepatitis B from by B-lymphocytes, among them highly polymeric bac- dialysis centres. The response to hepatitis B vaccine terial antigens, for instance Pneumococcal vaccine. proved to be a valid clinical index for individual Vaccination responses to Pneumococcus vaccine are immune reactivity in dialysis patients. normal in renal failure patients. These findings focused interest on T-cell activation as a crucial step to explain defective antigen specific immune responses in patients Cellular dysfunction: a defect of the antigen- with renal failure. presenting cell Lymphocyte numbers as well as the CD4/CD8 rela- tion are slightly diminished in dialysis patients, but Low response rates after vaccination against hepatitis these findings cannot explain reduced T-cell function. B lead to several studies on antigen-specific immune Although functional data suggested a defect of the T-lymphocytes, cell behaviour was entirely normal when activated in vitro in the presence of antigen-